Publications by authors named "A Telenti"

Background: There are three possible SARS-CoV-2 post-pandemic scenarios: (i) ongoing severity, (ii) influenza-like severity, and (iii) a transition to an endemic disease with lesser morbidity similar to that of other human coronaviruses.

Methods: To assess a possible evolution of the pandemic under the three scenarios, we use data from the US National Covid Cohort Collaborative, CDC COVID-NET, and CDC Fluview and from the WastewaterSCAN Dashboard. We include influenza disease and treatment response as benchmark.

View Article and Find Full Text PDF
Article Synopsis
  • - SARS-CoV-2 has evolved to evade current monoclonal antibodies (mAbs), emphasizing the need for more resilient treatments that can neutralize various viral strains.
  • - A new human mAb called VIR-7229 has shown the ability to effectively neutralize multiple variants of SARS-CoV-2 and other related viruses, due to its unique targeting of a critical viral region known as the receptor-binding motif (RBM).
  • - VIR-7229 demonstrates a high resistance to the emergence of virus escape mutants, making it a promising candidate for future therapies against evolving coronaviruses.
View Article and Find Full Text PDF
Article Synopsis
  • * The oligosaccharyltransferase (OST) complex, particularly the STT3A/B enzymes, plays a crucial role in this glycosylation and has emerged as a promising target for broad-spectrum antiviral drugs.
  • * The study highlights the balance between the antiviral potential of STT3A/B inhibitors, like NGI-1, and the need to assess their safety for humans, leading to the discovery of improved compounds that ensure both efficacy and lower toxicity risks.
View Article and Find Full Text PDF

Post-COVID-19 conditions (long COVID) has impacted many individuals, yet risk factors for this condition are poorly understood. This retrospective analysis of 88,943 COVID-19 patients at a multi-state US health system compares phenotypes, laboratory tests, medication orders, and outcomes for 1,086 long-COVID patients and their matched controls. We found that history of chronic pulmonary disease (CPD) (odds ratio: 1.

View Article and Find Full Text PDF